NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $91.06 -0.12 (-0.13 %) (As of 07/23/2018 06:46 AM ET)Previous Close$91.18Today's Range$89.1643 - $94.3952-Week Range$51.62 - $99.82Volume435,021 shsAverage Volume302,609 shsMarket Capitalization$5.25 billionP/E Ratio-13.49Dividend YieldN/ABeta2.01 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts. Receive AGIO News and Ratings via Email Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AGIO CUSIPN/A Webwww.agios.com Phone617-649-8600 Debt Debt-to-Equity RatioN/A Current Ratio10.75 Quick Ratio10.75 Price-To-Earnings Trailing P/E Ratio-13.49 Forward P/E Ratio-14.21 P/E GrowthN/A Sales & Book Value Annual Sales$43.01 million Price / Sales121.97 Cash FlowN/A Price / CashN/A Book Value$7.69 per share Price / Book11.84 Profitability EPS (Most Recent Fiscal Year)($6.75) Net Income$-314,670,000.00 Net Margins-822.32% Return on Equity-61.70% Return on Assets-43.75% Miscellaneous Employees382 Outstanding Shares57,610,000Market Cap$5,245.57 Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its quarterly earnings data on Friday, May, 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.60) by $0.03. The biopharmaceutical company had revenue of $8.80 million for the quarter, compared to the consensus estimate of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. Agios Pharmaceuticals's quarterly revenue was down 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.56) earnings per share. View Agios Pharmaceuticals' Earnings History. When is Agios Pharmaceuticals' next earnings date? Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Agios Pharmaceuticals. What price target have analysts set for AGIO? 13 equities research analysts have issued twelve-month price targets for Agios Pharmaceuticals' shares. Their predictions range from $80.00 to $125.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $96.70 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Ratings for Agios Pharmaceuticals. What is the consensus analysts' recommendation for Agios Pharmaceuticals? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Agios Pharmaceuticals stock? Here are some recent quotes from research analysts about Agios Pharmaceuticals stock: 1. Cann analysts commented, "We had anticipated FDA approval of Tibsovo (ivosidenib/AG-120) in late-August 2018. With the approval being granted one month ahead of schedule, the timing is supportive of our expected Q318 launch. We continue to believe ivosidenib will be a major driver of growth and value for Agios. Pricing for the drug at approximately $26,115 per month is in line with our estimate, as is the prescribed minimum duration of use. As a result of timing and pricing, our outlook remains positive and unchanged." (7/20/2018) 2. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018) Who are some of Agios Pharmaceuticals' key competitors? Some companies that are related to Agios Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE). Who are Agios Pharmaceuticals' key executives? Agios Pharmaceuticals' management team includes the folowing people: Dr. David P. Schenkein, CEO, Pres & Director (Age 61)Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)Mr. Andrew Hirsch, Chief Financial Officer (Age 47)Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)Dr. Christopher J. Bowden, Chief Medical Officer (Age 57) Has Agios Pharmaceuticals been receiving favorable news coverage? Media headlines about AGIO stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.73 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.09%), Handelsbanken Fonder AB (0.28%), Fred Alger Management Inc. (0.08%), Financial & Investment Management Group Ltd. (0.05%), Amalgamated Bank (0.02%) and Essex Investment Management Co. LLC (0.02%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals. Which major investors are selling Agios Pharmaceuticals stock? AGIO stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals. Which major investors are buying Agios Pharmaceuticals stock? AGIO stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Baillie Gifford & Co., Financial & Investment Management Group Ltd., Essex Investment Management Co. LLC, Creative Planning, Fox Run Management L.L.C., State of Alaska Department of Revenue and Amalgamated Bank. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $91.06. How big of a company is Agios Pharmaceuticals? Agios Pharmaceuticals has a market capitalization of $5.25 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected] MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 296 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 558MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?